Clinical Trials, Pipeline Developments, Financial Results, and New Appointments - Research Report on Amarin, Immunomedics,

      Clinical Trials, Pipeline Developments, Financial Results, and New
  Appointments - Research Report on Amarin, Immunomedics, Seattle Genetics,
                      Repros Therapeutics, and LifePoint

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, August 29, 2013

NEW YORK, August 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Amarin
Corporation plc (NASDAQ: AMRN), Immunomedics, Inc. (NASDAQ: IMMU), Seattle
Genetics, Inc. (NASDAQ: SGEN), Repros Therapeutics Inc. (NASDAQ: RPRX), and
LifePoint Hospitals, Inc. (NASDAQ: LPNT). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Amarin Corporation plc Research Report

On August 26, 2013, Amarin Corporation plc (Amarin) announced that it has
submitted a Supplemental New Drug Application (sNDA) to the US Food and Drug
Administration (FDA) for the approval of Novasep Group, S.A.S. (Novasep),
through its subsidiary Finorga S.A.S. (Finorga), as an additional Vascepa
(icosapent ethyl) active pharmaceutical ingredient (API) supplier. According
to the Company, this submission contributes to the planned expansion of the
Vascepa manufacturing supply chain and is additional progress toward the
Company's goal to protect the commercial potential of Vascepa to beyond 2030
through a combination of patent protection, regulatory exclusivity, trade
secrets and by taking advantage of manufacturing barriers to entry. Amarin
also informed that Novasep - a global leader in purification technologies and
API manufacturing, is building the world's largest chromatography plant using
its proprietary chromatography technologies, to produce API on behalf of the
Slanmhor consortium and Amarin. The Company anticipates this Novasep facility
in Mourenx, France, to be qualified and operational for manufacturing in 2014.
The Full Research Report on Amarin Corporation plc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/7cf9_AMRN]

--

Immunomedics, Inc. Research Report

On August 22, 2013, Immunomedics, Inc. (Immunomedics) reported its Q4 FY 2013
and full-year FY 2013 (period ended June 30, 2013). The Company's total
revenues increased 41.4% YoY to $1.4 million during Q4 FY 2013, but decreased
84.8% YoY to $5 million for FY 2013. Net loss attributable to Immunomedics
stockholders was $7.7 million or $0.09 per diluted share in Q4 FY 2013,
compared to net loss of $7.5 million or $0.10 per diluted share in Q4 FY 2012.
Net loss was $12.2 million or $0.16 per diluted share in full-year FY 2013,
compared to net income of $0.8 million or $0.01 per diluted share in FY 2012.
Gerard G. Gorman, Senior Vice President Finance and CFO, said, "In order to
continue the clinical development of our antibody-drug conjugate programs in
patients with solid tumors, which have advanced into Phase II trials, and to
pay for certain expenses to initiate the planned clivatuzumab trial for the
treatment of patients with pancreatic cancer, which we anticipate to advance
into Phase III in fiscal 2014, we expect cash requirements in fiscal year 2014
to increase to $24 to $26 million." The Full Research Report on Immunomedics,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/c20d_IMMU]

--

Seattle Genetics, Inc. Research Report

On August 15, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced that
it has initiated Phase 2 clinical trial evaluating ADCETRIS (brentuximab
vedotin) in combination with RCHOP (A+RCHOP), the current standard frontline
therapy, for newly diagnosed patients with diffuse large B-cell lymphoma
(DLBCL). According to the Company, the primary object of study is to assess
the complete remission rate and safety profile of the combination, while
secondary endpoints include objective response rate, progression-free survival
and overall survival. Clay B. Siegall, Ph.D., President and CEO at Seattle
Genetics, said, "This trial will provide us with data on the tolerability of
the combination, as well as the antitumor activity achieved by adding ADCETRIS
to the current standard frontline regimen. In addition, based on interim
findings from our trial in the relapsed setting in which objective responses
were observed among patients with low or undetectable levels of CD30 by
conventional screening methods, we will enroll high-risk DLBCL patients to
this frontline trial without prescreening for CD30 expression." The Full
Research Report on Seattle Genetics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/ff98_SGEN]

--

Repros Therapeutics Inc. Research Report

On August 20, 2013, Repros Therapeutics Inc. (Repros) reported interim 6 month
results from the first 150 subjects enrolled into the ongoing one year placebo
controlled study to assess the effect of Androxal treatment of secondary
hypogonadal men and its effects on bone mineral density. The Company stated
that at the 6 month time point, there is no proof that Androxal reduces bone
mineral density as assessed by DEXA scans. Repros also said that there is a
consistent trend in many bone regions where an improvement of bone mineral in
comparison to placebo is observed. The Company expects that topline results
from the first 150 subjects who completed 12 months of exposure to be
available by Q2 2014 and also said that the New Drug Application (NDA) for
Androxal remains on track for submission in mid-2014. The Full Research Report
on Repros Therapeutics Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/2334_RPRX]

--

LifePoint Hospitals, Inc. Research Report

On August 21, 2013, LifePoint Hospitals, Inc. (LifePoint) announced the
appointment of Leif Murphy as the CFO, with effect from September 14, 2013.
According to the Company, Murphy holds nearly 20 years of healthcare finance
and development experience and prior to joining LifePoint in 2011, Murphy
served as President and CEO of DSI Renal, Inc., and was also Senior Vice
President and Treasurer at Caremark, Inc. The Full Research Report on
LifePoint Hospitals, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/f06d_LPNT]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)